BST Position Update – April 1, 2015

| April 1, 2015

BST Position Update

. . . . Dyax (NASDAQ: DYAX) – Hold

Boom! Dyax’s drug known as DX-2930, was found to have eliminated all attacks of hereditary angioedema, or HAE, when taken at doses of 300 milligrams. In others words, Dyax has found a cure for HAE.

Not surprisingly, this drug is being fast tracked by the FDA.

I hope your seat belt is buckled because this stock is ready for takeoff… in fact, it’s already up nearly 70%.

The company that developed the drug that is currently the primary treatment for HAE was purchased for a whopping $4.2 billion in 2013.

I wouldn’t be surprised to see a similar offer from a big drug maker for Dyax soon. If the buyout offer comes, the stock could easily double or triple in value from here.

Continue holding for bigger gains.

. . . . Lpath (NASDAQ: LPTN) – Hold

Lpath recently reported disappointing results from a phase 2 trial of ASONEP. This is a major setback for this developmental stage company.

But don’t forget, ASONEP isn’t the only potential catalyst for LPTN. Lpath also has an ongoing phase 2 trial for a drug called iSONEP.

We thought all along that iSONEP was the leading drug candidate for Lpath. These trial results are expected sometime in the next few months.

Continue holding.

Action To Take

  • None at this time


Category: BST Update

About the Author ()

Comments are closed.